A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT02996110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Study identification
- NCT ID
- NCT02996110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Relatlimab Biological
- BMS-986205 Drug
- BMS-813160 Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2017 (Actual)
- Primary completion
- Nov 23, 2021 (Actual)
- Completion
- Nov 23, 2021 (Actual)
- Last update posted
- Dec 19, 2022
2017 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 18
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0037 | New Haven | Connecticut | 06520 | — |
| Local Institution | Tampa | Florida | 33612-9497 | — |
| Local Institution - 0031 | Augusta | Georgia | 30912 | — |
| Local Institution - 0006 | Chicago | Illinois | 60612 | — |
| Local Institution - 0007 | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| Local Institution - 0011 | Detroit | Michigan | 48201 | — |
| Local Institution - 0008 | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Local Institution - 0005 | New York | New York | 10065 | — |
| Local Institution - 0043 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0014 | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Local Institution - 0002 | Allentown | Pennsylvania | 18103 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Local Institution - 0025 | Nashville | Tennessee | 37203 | — |
| Ut Southwestern Medical Center | Dallas | Texas | 75390-8570 | — |
| Local Institution - 0024 | Charlottesville | Virginia | 22908 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02996110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2022 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02996110 live on ClinicalTrials.gov.